Olmedo, Maria Eugenia Cervera, Raquel Cabezon-Gutierrez, Luis Lage, Yolanda Corral de la Fuente, Elena Gómez Rueda, Ana Mielgo-Rubio, Xabier Trujillo, Juan Carlos Couñago, Felipe
Published in
World Journal of Clinical Oncology
The 2004 discovery of EGFR mutations, followed by ALK rearrangements, ushered in a targeted therapy era for advanced non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting gene alterations have substantially improved survival and quality of life for patients with NSCLC. In the last decade, rearrangements of the ROS1 oncogene have ...
Sunpaweravong, Patrapim Thongwatchara, Patcharaporn Chotipanvithayakul, Rassamee Sangkhathat, Surasak Thongsuksai, Paramee
Published in
Clinical Medicine Insights. Oncology
Background: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer death worldwide, for which better knowledge in molecular prognostic factors is needed to improve clinical outcome. This study aimed to investigate the clinical significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 in NSCLC patients. Methods: Formalin-fixed paraffin-embedde...
Liu, Ke Li, Jiaoyuan Long, Tingting Wang, Yi Yin, Tongxin Long, Jieyi Shen, Ying Cheng, Liming
Published in
PeerJ
Background Previous studies have shown the alteration of amino acid (AA) profile in patients with non-small cell lung cancer (NSCLC). However, there is little data regarding AA profile in NSCLC in Chinese population. The aim of this study was to evaluate AA profile in Chinese NSCLC patients, explore its utility in sample classification and further ...
Li, Dongliang Fu, Zejun Dong, Chaoqun Song, Yongming
Published in
Bioengineered
Zhang, Lin Lin, Weihao Tan, Fengwei Li, Ning Xue, Qi Gao, Shugeng Gao, Yibo He, Jie
Published in
Biomarker Research
Anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunotherapy has dramatically changed the therapeutic landscape of inoperable non-small cell lung cancer (NSCLC), and has been included in first-line treatments. Sintilimab is a domestic anti-PD-1 monoclonal antibody in China that has received approvals from the National Medical Prod...
Adib, Elio Nassar, Amin H. Abou Alaiwi, Sarah Groha, Stefan Akl, Elie W. Sholl, Lynette M. Michael, Kesi S. Awad, Mark M. Jӓnne, Pasi A. Gusev, Alexander
...
Published in
Genome Medicine
Background Genomic alterations in 8 genes are now the targets of FDA-approved therapeutics in non-small cell lung cancer (NSCLC), but their distribution according to genetic ancestry, sex, histology, and smoking is not well established. Methods Using multi-institutional genetic testing data from GENIE, we characterize the distribution of targetable...
Zhu, Jian-man Sun, Lei Wang, Linjing Zhou, Tong-Chong Yuan, Yawei Zhen, Xin Liao, Zhi-Wei
Published in
BMC Research Notes
Objective This study was to explore the most appropriate radiomics modeling method to predict the progression-free survival of EGFR-TKI treatment in advanced non-small cell lung cancer with EGFR mutations. Different machine learning methods may vary considerably and the selection of a proper model is essential for accurate treatment outcome predict...
Lee, Natalie Si-Yi Shafiq, Jesmin Field, Matthew Fiddler, Caroline Varadarajan, Suganthy Gandhidasan, Senthilkumar Hau, Eric Vinod, Shalini Kavita
Published in
Radiation Oncology (London, England)
Background There are limited data on survival prediction models in contemporary inoperable non-small cell lung cancer (NSCLC) patients. The objective of this study was to develop and validate a survival prediction model in a cohort of inoperable stage I-III NSCLC patients treated with radiotherapy. Methods Data from inoperable stage I-III NSCLC pat...
Zaim, Remziye Redekop, Ken Uyl-de Groot, Carin A.
Published in
Translational Oncology
In the era of value-based oncology care, stakeholders are increasingly using patient reported outcomes (PROs) to guide clinical and regulatory decisions. PROs are also included in health technology assessments to guide patient access, drug reimbursement and pricing. We reviewed PROs collected in the United States Food and Drug Administration approv...
Ma, Si-Cong Bai, Xue Guo, Xue-Jun Liu, Li Xiao, Lu-Shan Lin, Yan Tan, Jia-Le Cai, Xiao-Ting Wen, Yu-Xiang Ma, Hu
...
Published in
BMC Medicine
Background Organ-specific metastatic context has not been incorporated into the clinical practice of guiding programmed death-(ligand) 1 [PD-(L)1] blockade, due to a lack of understanding of its predictive versus prognostic value. We aim at delineating and then incorporating both the predictive and prognostic effects of the metastatic-organ landsca...
